about
Immunogenomics and systems biology of vaccines.The hows and whys of constructing a native recombinant cholera vaccine.Vaccines against human diarrheal pathogens: current status and perspectivesNewer insights into the mechanism of action of Psidium guajava L. leaves in infectious diarrhoeaA single point mutation within the coding sequence of cholera toxin B subunit will increase its expression yieldSevere, acute watery diarrhea in an adult.Active immunization in the United States: developments over the past decade.Endemic infectious diseases of Afghanistan.Bacterial infectious disease control by vaccine development.Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera.Survey of human-use adjuvants.Vital role of medical examiners and coroners in organ transplantation.Perceptions of Health Communication, Water Treatment and Sanitation in Artibonite Department, Haiti, March-April 2012.Enteric pathogens as vaccine vectors for foreign antigen deliveryConstruction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108Oral delivery of bioencapsulated exendin-4 expressed in chloroplasts lowers blood glucose level in mice and stimulates insulin secretion in beta-TC6 cells.Live attenuated oral cholera vaccines.The ABCs (Antibody, B cells, and Carbohydrate epitopes) of cholera immunity: considerations for an improved vaccine.Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice.Postgenomics of Neisseria meningitidis for vaccines development.Why is the oral cholera vaccine not considered an option for prevention of cholera in India? Analysis of possible reasonsHuman prophylactic vaccine adjuvants and their determinant role in new vaccine formulations.Adjuvants for foot-and-mouth disease virus vaccines: recent progress.Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines.
P2860
Q33350387-82DFB426-3240-440B-8D80-AF76175657A3Q33560076-E06AC888-67F4-432B-9810-998ABD1E2546Q33578045-AF67878A-75E6-48B1-959B-0BD6A4877E77Q33618359-8500C53B-D21D-481C-8545-D5DB4D7D22DBQ33722430-28E5ADE4-041C-44B2-8697-30F97E42E55DQ33769896-72B15A67-7954-4C04-BB95-EAB51F435291Q33975799-77EB3749-0BA7-4310-B851-D5D5CE2BC73FQ34645383-43B9382C-BDCD-4656-82BC-68E5958EBE6BQ34785982-F9D10EA4-2206-4328-8A7D-DDBC9CED740BQ35066200-6BBF0456-06F1-4C5F-B884-101C3EFC8E81Q35192171-173D2D75-3AA1-4121-BD3C-184C304D68D7Q35671634-868F3AF4-8445-4322-ACC3-39F058591D69Q35839967-1D92395B-A925-4CFD-BE55-B26304598917Q35896020-83B802A4-F443-4328-B1A5-61EE1489B481Q36045133-59C819F4-B96D-4646-886F-268024CCA789Q36504504-5005C1EA-15A7-48F6-BBC6-2635EB5EAA62Q36600341-38EA4F54-D097-4B81-BCEB-041051EF8828Q36688241-0970F594-8533-454C-BAC5-9FC72B41265AQ36898523-40F52E76-4149-435C-A45C-5FD65557A99BQ36973781-3BD108AD-96DD-498D-AE5A-0A7B9C8C5CACQ37186557-BA6D0940-BB7C-4AFE-8938-B4E983833D39Q37371036-B9015A0A-4706-4FAB-B37F-48B9F25709C3Q38252451-79B6927D-CF7B-401F-9A47-25F6E6021725Q40571679-B59885FD-FD5D-4A33-A5D0-760FBD40569B
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Cholera vaccines.
@ast
Cholera vaccines.
@en
Cholera vaccines.
@nl
type
label
Cholera vaccines.
@ast
Cholera vaccines.
@en
Cholera vaccines.
@nl
prefLabel
Cholera vaccines.
@ast
Cholera vaccines.
@en
Cholera vaccines.
@nl
P356
P1476
Cholera vaccines.
@en
P2093
S B Calderwood
P304
P356
10.1086/313951
P407
P577
2000-08-01T00:00:00Z